CAS 364779-14-6: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(5-methyl-1-methylene-hex-4-enyl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]tetrahydropyran-3,4,5-triol

Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities.

Ginsenoside Rk2 is a bioactive compound, specifically a saponin, which is extracted from the root of Panax ginseng, a plant traditionally used in Asian medicine. The mode of action of Ginsenoside Rk2 involves modulating various cellular pathways, including influencing gene expression and enzyme activity, which contribute to its diverse physiological effects. It has been studied for its potential to impact cell signaling mechanisms, including those involved in inflammation, oxidative stress, and apoptosis. Ginsenoside Rk2's primary applications center around its research potential in pharmacology and medicine. It is predominantly explored for its role in anti-cancer therapies, due to its ability to induce cell cycle arrest and promote apoptosis in cancer cells. Additionally, Rk2 is investigated for its neuroprotective effects, possibly offering insights into managing neurodegenerative disorders. Its anti-inflammatory properties are also of interest in studies related to chronic inflammatory diseases. As research continues, Ginsenoside Rk2 holds promise for contributing valuable insights into new therapeutic approaches targeting multiple biochemical pathways.